Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Clinical trial NCT07531095 · RECRUITING
Trial details
- NCT number
- NCT07531095
- Sponsor
- Amgen
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-21
- Primary completion
- 2028-05-21
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.